Tissue Cure Alliance is a platform for Novel Finnish Tissue Regeneration and Wound Care Products and Solutions

Tissue Cure Alliance Finland

Tissue Cure Alliance Finland is a non-profit community for Finnish tissue regeneration and wound care companies and research organisations. The Alliance offers access to specialized knowledge and expertise and enables participants to expand their professional network. Sharing experiences and best practises is at the heart of the Alliance. In addition, the Alliance aims at promoting and marketing the products and solutions provided by its members.

The Alliance acts as a platform for people and organisations in the field to meet and exchange knowledge and experience. In its role as facilitator and enabler, the Alliance arranges scientific seminars, networking and promotional events.
Members present their products and solutions under the common brand of the Alliance.


Finland’s high level of education, public sector research funding and science and technology policies that emphasize Finland’s own national expertise have created the preconditions for a high-tech success story.

The Alliance was founded in 2018 by Finnish start-up companies Askel Healthcare Oy, CutoSense Oy, Finnish Red Cross Blood Service, UPM Biomedicals and Åbo Akademi University.

Growing interest

By 2020 the global wound care market is expected to reach $22bn (~€19bn), according to market research firm MarketsandMarkets™ – a growth it attributes to an increasing prevalence of chronic and acute wounds, a rising number of road traffic accidents, a rapidly ageing population, a greater interest in wound care research, and a growing awareness of wound care treatment and management.

Full members

• will get their logo on TCAF publications and a short presentationon the TCAF homepage
• have voting rights at TCAF members’ meetings
may use the text “Member of Tissue Cure Alliance Finland” together with TCAF logo in their marketing

monthly subscription fees (+VAT)
three categories:

• Start-ups 150 €
• Academic and not-for-profit organizations 300 €
Growth companies 450 €

Associate members

• can benefit and also contribute by being part of the TCAF network
• may participate in all events arranged by the Alliance, but have
• no voting rights
• for small organisations (<10) and research groups

yearly subscription fee 150 € (+VAT)

TCAF Chairman of the Board
Virpi Muhonen

Askel Healthcare Oy
Kuortaneenkatu 2
e-mail: firstname.lastname @ askelhealthcare.com

TCAF Coordinator
Andreas Slama

Oy Konfer Ab
Uudenmaankatu 1 A
20500 TURKU
e-mail: info @ tissuecure.fi


Askel Healthcare – rebuilding healthy joint surfaces for pain-free movement 

Cartilage-related problems are the most frequently encountered problems orthopaedic surgeons face in their practice. Despite the prevalence of the problem, there are no treatments available for restoring and maintaining the original functionality of the tissue. Whatever the cause, cartilage destruction consistently results in pain and lameness, adversely affecting the lifestyle and activity levels of the afflicted.
The scientific team at Askel Healthcare has developed a medical device, called the COPLA® Scaffold, providing for the first time in the world the almost unhealable tissue with the capacity to heal.

For more information please visit

Our company is specialised in developing wound-measurement and -treatment systems

The company continues to cooperate with universities and the latest research. CutoSense Oy was founded in 2016 after long scientific research resulting in a joint project with Tekes (a govermental organisation).

Our solution for chronic wounds, WoundWatch™ is a treating and monitoring solution.
The system has been clinically tested at Tampere University Hospital on patients with chronic lower-limb ulcers. The mapping functionality was found to accurately depict actual changes in wound status. The possibility to minimise the need for dressing removals and visual inspection as a follow-up procedure allows for significant cost-savings and reduced discomfort for patients.
We are now productising WoundWatch™ to gain the CE-certification in late 2018/early 2019.

For more information please visit

Cell Therapy For Wound Repair And Skin Regeneration

Research at CardioReg focuses on both preclinical and clinical aspects of tissue regeneration. Special emphasis is on cardiac regeneration and wound healing.
We utilize preclinical research methodologies for drug target discovery and elucidation of specific disease-associated pathological processes. We are located at the Meilahti Hospital campus as part of the Academic Medical Center Helsinki and work in close collaboration with cardiac surgeons, cardiologists, plastic surgeons, burn surgeons, anaesthesiologists and radiologists.
Our research aims at guiding inherent regenerative responses with pharmacotherapy as well as stem and progenitor cells. We also evaluate the possibilities of various gene therapymodalities in these settings.

For more information please visit

The Finnish Red Cross Blood Service: we create potential for saving lives

The Finnish Red Cross Blood Service (FRCBS) is the nationwide blood service provider in Finland and our main task is to provide the Finnish hospitals with various blood products for treating patients. We also offer hospitals laboratory services, such as blood group testing and laboratory tests related to organ, tissue and stem cell transplantations and blood coagulation. The FRCBS is also active in the cell therapy field and hosts the Advanced Cell Therapy Centre with its GMP facilities for the development and manufacturing of novel cell therapy products. Hosting the Finnish Stem Cell Registry, the Blood Service Biobank and the Finnish Hematological Registry and Biobank is also part of our tasks. Research is conducted on operative areas of the FRCBS, in particular transfusion medicine and cell and tissue therapies, and we produce approx. 30-40 scientific publications each year. We are a not-for-profit organisation, and our prime concern is what is best for the patient.

For more information please visit

UPM Biomedicals develops and supplies innovative and sustainable wood-based biomedical products for a variety of uses.

UPM Biomedicals provides animal free, bio-friendly hydrogels and other solutions for biomedical applications. Our high-quality products are derived from renewable wood sources originating from sustainably managed and certified forests. We are part of UPM – The Biofore Company.

GrowDex® product family is a nanofibrilar cellulose hydrogel for 3D cell culturing and other biomedical applications. GrowDex® is ready to use and room temperature stable hydrogel that mimics the extracellular matrix (ECM) and supports cell growth and differentiation with consistent results. It is highly biocompatible with human cells and tissues – but free from any animal- or human-derived material. Bridging the gap between in vitro and in vivo studies, GrowDex can be used for 3D cell culture, for spheroid or organoids formation, for drug discovery, in personalised medicine, regenerative medicine, organ-on-a-chip models, drug release studies, 3D printing and much more.

For more information please visit

Åbo Akademi University – high-level research in life sciences, materials and technologies for health

Åbo Akademi University’s strategy, “Åbo Akademi – breaking boundaries”, for the years 2015–2020 is the profiling of research within our strongest fields. A central aspect within two of these interrelated research profiling areas, Molecular Process and Material Technology and Drug Discovery and Diagnostics (DDD) aim to develop new advanced materials and technologies for health. Further, collaboration between DDD and the Minority profiling area will address societal and ethical issues related to patient care, utilization of medical information as well as research results. The DDD Platform is a joint research profiling area of the University of Turku and ÅAU, since drug discovery, development and diagnostics have a long history and a broad knowledge-base in Turku. ÅAU has internationally high-level expertise in research areas relevant to the DDD profiling area: pharmaceutical sciences, molecular cell biology, biochemistry, computer-aided drug discovery and drug design, chemistry, physics and material sciences. The two Universities have for decades worked closely together to develop cutting-edge infrastructure for biomedical research. Prime examples of this are the joint biocentre, BioCity Turku (www.biocity.turku.fi), and two special independent departments, the Turku Positron Emission Tomography (PET) Centre (www.turkupetcentre.fi) and the Turku Centre for Biotechnology (www.btk.fi), which provide state-of-the art infrastructures to the entire Turku research community. In addition, Turku Bioimaging (www.bioimaging.fi), the Turku Center for Disease Modeling (www.tcdm.fi), the new Auria Biobank (https://www.auriabiopankki.fi/en/) and the Turku Brain and Mind Center (www.utu.fi/en/units/tbmc/) are important parts of the local infrastructure that provide and coordinate technologies closely related to the life sciences.

For more information please visit

Latest News and Coming Events

Event When Where Website
ISCT 2020 MAY 27-30 VIRTUAL www.isct2020.com
EWMA (European Wound Management Association) NOV 13-15 ExCeL London www.ewma.org
ChemBio APR 27-28 Messukeskus Helsinki https://chembio.messukeskus.com/


Would you like to get regular updates from Tissue Care Alliance Finland? 
Leave your e-mail and we’ll add you to our mailing list.

Copyright © Tissue Cure Alliance Finland 2020 Design by Mainostoimisto Urmas